Rubi Schildgen

Study plans to investigate elinzanetant as non-hormonal treatment for vasomotor symptoms caused by endocrine therapy in breast cancer patients  / Elinzanetant is an innovative non-hormonal development compound in development for the treatment of vasomotor symptoms during menopause Berlin, October 17, 2022 – Bayer, a global leader in women’s healthcare...